Vobramitamab duocarmazine  (Synonyms: AEX4089DC1; MGC018)

Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity^[1].

Vobramitamab duocarmazine (MGC018; for 7 days) exhibits cytotoxicity toward B7-H3-positive human tumor cell lines, including MDA-MB-468, A375.S2, PA-1, Calu-6, NCI-H1703, Hs700T, LN-229, and SW48 cancer cells, with IC₅₀ values range of 181-1447 pM. Vobramitamab duocarmazine exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3-positive tumor cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vobramitamab duocarmazine (MGC018; 3-6 mg/kg; i.v; single-dose) leads to a dose-dependent decrease in tumor growth of MDA-MB-468 triple-negative breast cancer xenografts^[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) leads to a rapid tumor regression, with a 98% reduction in tumor volume in a triple-negative breast cancer patient-derived xenograft (PDX) model^[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in the PA-1 ovarian cancer xenografts. A reduction in tumor volume of 89%, 91%, and 43%, is observed following treatment with Vobramitamab duocarmazine at 10, 6, and 3 mg/kg, respectively^[1].
Vobramitamab duocarmazine (MGC018; 1-3 mg/kg; i.v; single-dose) shows antitumor activity in A375.S2 melanoma xenografts^[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in Calu-6 lung cancer xenografts. A reduction in tumor volume of 91%, 84%, and 72% is observed following treatment with Vobramitamab duocarmazine at 10 mg/kg, 6 mg/kg, and 3 mg/kg, respectively^[1].
Vobramitamab duocarmazine (MGC018; 3 mg/kg; QW×3 or Q2W×2; i.v) shows antitumor activity toward patient-derived xenograft models of prostate, and head and neck cancer displaying heterogeneous expression of B7-H3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2490556-51-7

Liquid

Colorless to light yellow

[Vobramitamab duocarmazine]

Shipping with dry ice.

-80°C, protect from light

• [1]. Juniper A Scribner, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19(11):2235-2244.  [Content Brief]